You could easily point out Mylan's (NASDAQ: MYL) trouble spot on a map when the drugmaker reported its third-quarter results in November. The company struggled mightily in the U.S. because of a laundry list of problems. However, things looked much better for Mylan on the international front.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,